疫苗ETF（159643）涨超1.8%，产业迎全球化价值重估

Group 1 - The core viewpoint of the article highlights that the Chinese pharmaceutical industry has completed a transformation from old to new growth drivers, focusing on innovation over imitation, and enhancing its global competitiveness [1] - The vaccine ETF (159643) rose over 1.8%, indicating a global revaluation of the industry [1] - China's innovative pharmaceutical sector has gained scale, with traditional pharmaceutical companies successfully transitioning to innovation-driven models, and innovative drug companies rapidly emerging [1] Group 2 - Chinese pharmaceutical companies are increasingly recognized as significant sources of innovation by multinational pharmaceutical firms, with medical devices and supply chains achieving a strong global presence [1] - Demand and payment mechanisms are continuously driving new growth, with an accelerating aging population and rising chronic disease needs, alongside steady growth in health insurance revenue [1] - New technologies, particularly in AI, are expected to accelerate industry transformation, with developments in brain-computer interfaces, early cancer screening, and AI healthcare [1] Group 3 - The vaccine ETF tracks the vaccine biotechnology index (980015), which selects listed companies involved in biological products and medical research from the Shanghai and Shenzhen markets, focusing on those with strong innovation capabilities and high R&D investment [1]